Introduction {#sec1}
============

The updated results of the KEYNOTE-001 study have confirmed the revolutionary impact of the anti-programmed death-1 agent pembrolizumab on outcomes of patients with advanced non--small-cell lung cancer (NSCLC) whose tumors lack actionable oncogenic drivers.[@bib1], [@bib2], [@bib3] The widespread adoption of anti-programmed death-1 agents and durable responses seen in some patients have raised important questions regarding the optimal frequency of administration of these drugs, including the impact of treatment interruptions or discontinuations in routine clinical practice.[@bib4] Although immune-related adverse events (irAEs) have been associated with improved outcomes in NSCLC,[@bib5] ^,^ [@bib6] a retrospective study in Canada suggested lower overall survival (OS) in patients receiving interrupted treatments owing to irAEs.[@bib7] Additionally, the lowest and least frequent dose of pembrolizumab that may permit maximal efficacy in advanced NSCLC is still unknown.[@bib4] ^,^ [@bib8] Moreover, the financial and societal impacts of access to this durably efficacious therapy for this growing population necessitates thoughtful consideration of resource utilization and the patient care experience so as to afford an optimized and sustainable care paradigm for all those who may benefit.[@bib4] ^,^ [@bib9] ^,^ [@bib10]

Recent efforts to develop less frequent and more flexible dosing regimens have included the phase IIIb/IV CheckMate 384 study of nivolumab in advanced NSCLC, which confirmed similar efficacy and safety outcomes with 480 mg every 4 weeks compared with 240 mg every 2 weeks, as predicted by exposure-response evaluations.[@bib11] ^,^ [@bib12] A modeling/simulation study, based on the established pharmacokinetic model of pembrolizumab from early developmental trials, predicted that a dose of 400 mg every 6 weeks would be equally as effective as the standard United States Food and Drug Administration (FDA)-approved dose of 200 mg every 3 weeks.[@bib13]

However, clinical evaluations of these alternate dosing schemas have not yet been performed. We conducted a multicenter retrospective study to evaluate survival outcomes of patients with advanced NSCLC who were treated with pembrolizumab-based regimens at standard versus extended intervals in routine clinical practice.

Patients and Methods {#sec2}
====================

In this retrospective cohort study, medical charts from 2 tertiary academic cancer centers, Beth Israel Deaconess Medical Center (BIDMC)/Harvard Medical School and Vidant Medical Center (VMC)/Brody School of Medicine at East Carolina University, were reviewed in accordance with research protocols approved by the respective institutional review boards. Patients with advanced NSCLC (defined as patients with stage IV or recurrent advanced disease, who were not candidates for curative intent treatment) who received pembrolizumab-based regimens (defined as first-time patients who were treated with pembrolizumab in the palliative care setting, either as monotherapy or along with chemotherapy) for at least 4 cycles in routine practice outside clinical trials at either BIDMC or VMC between February 1, 2016 and April 5, 2019 were eligible. Those who started their first pembrolizumab-based regimen outside these 2 centers were excluded from the study. Patients eligible for the study were divided into 2 groups: (1) the nonstandard group (Non-Std: those receiving pembrolizumab 200 mg for ≥ 2 cycles at intervals \> 3 weeks + 3 days for any reason), and (2) the standard group (Std: either all treatment cycles at FDA-approved dose interval or up to 1 cycle at interval \> 3 weeks + 3 days for any reason). The objective of this study was to evaluate if patients with advanced NSCLC belonging to the Non-Std group had worse OS or progression-free survival (PFS) compared with the Std group.

Patient data was collected on demographics, clinicopathologic characteristics, treatment regimen details, and irAEs. Patient characteristics such as age and Eastern Cooperative Oncology Group performance status, survival time, and duration of response were calculated from the start of first pembrolizumab-based treatment, until progression or switch to alternative/additional therapy. Tumor molecular profile and mutational burden were evaluated in these patients by different multiplex next-generation sequencing platforms as well as polymerase chain reaction and fluorescence in-situ hybridization for individual mutations/rearrangements. Disease response was evaluated by thoracic radiologists using the immune Response Evaluation Criteria in Solid Tumors (iRECIST).[@bib14] Descriptive tables were generated, depicting proportions for categorical variables and median (with range) for noncategorical variables. The Fisher exact and Wilcoxon rank sum tests were used to calculate 2-sided *P* values for categorical and continuous outcomes, respectively. Kaplan-Meier survival curves and the log-rank test were employed for analysis of censored survival outcomes. Six-month landmark analysis was performed to account for immortal time bias. Univariate and multivariable regression to adjust for confounding variables were performed using Cox proportional hazards model. A Swimmer plot was generated to depict the duration of response from the first nonstandard cycle in the Non-Std group. A 2-sided *P* value \< .05 was considered significant. Adjustments for multiple comparisons were not made owing to the exploratory nature of this analysis. Graph creation and statistical analysis were performed using Microsoft Excel and Stata/IC v15.1 software.

Results {#sec3}
=======

Of 150 patient charts reviewed from both centers, 92 (61%) patients had received at least 4 cycles of pembrolizumab-based regimens and were eligible for the study ([Figure 1](#fig1){ref-type="fig"} , which demonstrates distribution of screened patients, and [Supplemental Table 1](#tblS1){ref-type="table"} \[in the online version\], which demonstrates characteristics of included and excluded patients). Twenty-seven (29%) patients were classified in the Non-Std group, whereas 65 (71%) belonged to the Std group. Among the Non-Std group patients, 16 had treatment delays owing to irAEs (9; 33%) or non--irAE-related medical issues (7; 26%) (see [Supplemental Table 2](#tblS2){ref-type="table"} in the online version). Eleven (41%) patients opted to receive treatments at extended dosing intervals after a detailed discussion with their physicians. [Table 1](#tbl1){ref-type="table"} summarizes the patient characteristics of the Non-Std and Std groups. Patients in the Std group were more likely to receive pembrolizumab along with chemotherapy (Non-Std: 29% vs. Std: 66%; *P* = .002) and have tumors with lower programmed death-ligand 1 tumor proportion score (*P* = .01). Patients in the Non-Std group were more likely to have a higher number of treatment cycles (Non-Std: 14 vs. Std: 6; *P* \< .0001).Figure 1Distribution of Patients With Advanced NSCLC Screened in the StudyAbbreviations: IHC = Immunohistochemistry; irAE = immune-related adverse event; NSCLC = non--small-cell lung cancer; PD-L1 = programmed death-ligand 1; TPS = tumor proportion score.Table 1Patient Characteristics in the Nonstandard Versus Standard GroupsAll Patients (N = 92)Standard Group (N = 65)Nonstandard Group (N = 27)Clinico-pathologic characteristics Median age, y (range)64.5 (37-87)64 (49-87)66 (37-87) Female gender44 (48)31 (48)13 (48) Smoking status, ever84 (91)58 (89)26 (96) ECOG PS 0-175 (82)54 (83)21 (78) ≥ 217 (18)11 (17)6 (22) Histology Non-squamous70 (76)49 (75)21 (78) Squamous15 (16)11 (17)4 (15) Poorly differentiated7 (8)5 (8)2 (7) Driver mutation *KRAS*33 (36)26 (40)7 (26) *EGFR*6 (7)3 (5)3 (11) Others3 (3)2 (3)1 (4) None identified40 (43)27 (41)13 (48) Not assessed10 (11)7 (11)3 (11) PD-L1 TPS, % \<124 (26)22 (34)2 (7) 1-4917 (18)9 (14)8 (30) ≥5042 (46)28 (43)14 (52) Not assessed9 (10)6 (9)3 (11) TMB, mut/mB \<1020 (22)16 (25)4 (15) ≥1030 (32)19 (29)11 (41) Not assessed42 (46)30 (46)12 (44)Treatment characteristics Line of pembrolizumab First line65 (71)50 (77)15 (56) ≥Second line27 (29)15 (23)12 (44) Treatment Monotherapy41 (45)22 (34)19 (71) With chemotherapy51 (55)43 (66)8 (29) Treatment center BIDMC47 (51)29 (45)18 (67) VMC45 (49)36 (55)9 (33) Median no. of treatment cycles (range)8 (4-41)6 (4-20)14 (6-41) Best response Progression7 (8)6 (9)1 (4) Clinical benefit83 (90)57 (88)26 (96) CR15 (16)12 (19)3 (11) PR40 (44)25 (38)15 (56) SD28 (30)20 (31)8 (30) Not available2 (2)2 (3)- Any grade irAE, yes54 (59)35 (54)19 (70) ≥Grade 3 irAE, yes28 (30)21 (32)7 (26) Systemic immunosuppression, yes41 (45)29 (45)12 (44)[^2][^3]

The median OS was not reached (NR) in the Non-Std group and was significantly longer compared with the Std group by univariate analysis (Std: 15.4 months; 95% confidence interval \[CI\], 9.0 months to NR vs. Non-Std: NR; 95% CI, NR) ([Figure 2A](#fig2){ref-type="fig"} , [Supplemental Table 3](#tblS3){ref-type="table"} \[in the online version\]). The median PFS was also significantly longer in the Non-Std group compared with the Std group by univariate analysis (Std: 7.0 months; 95% CI, 5.1-8.8 months vs. Non-Std: 23.3 months; 95% CI, 14.6 months to NR) ([Figure 2B](#fig2){ref-type="fig"}, [Supplementa Table 4](#tblS4){ref-type="table"} \[in the online version\]). Six-month landmark analyses continued to show significant differences in both OS (Std: 34.9 months; 95% CI, 15.4 months to NR vs. Non-Std: NR; 95% CI, NR) and PFS (Std: 11.8 months; 95% CI, 8.8 months to NR vs. Non-Std: NR; 95% CI, 14.6 months to NR) between the 2 groups ([Figure 2C-D](#fig2){ref-type="fig"}). However, after adjustment with multivariable regression (stratified by immune-related adverse events owing to its time-variant nature), no significant differences were seen in OS (hazard ratio \[HR\] for death, 1.2; 95% CI, 0.3-4.8) or PFS (HR for disease progression or death, 2.6; 95% CI, 0.7-9.6) between the Non-Std and Std groups ([Tables 2](#tbl2){ref-type="table"} and [3](#tbl3){ref-type="table"} ). Swimmers' plots for patients belonging to the Non-Std group showed that most patients received their first nonstandard cycle within 6 months of start of therapy, with most having sustained responses ([Figure 3](#fig3){ref-type="fig"} ). Univariate analyses of OS and PFS by the 3 predominant indications for nonstandard dosing in the Non-Std group compared with the Std group showed statistically significant differences favoring the Non-Std subgroups --- except for OS relating to the patient-physician preference (see [Supplemental Figure 1](#figS1){ref-type="fig"} in the online version).Figure 2Univariate Kaplan-Meier Survival Curves in Patients With Advanced NSCLC Belonging to Nonstandard Versus Standard Groups for Overall Survival (**A**), Progression-free Survival (**B**), 6-month Landmark Overall Survival (**C**), and 6-month Landmark Progression-free Survival (**D**)Abbreviations: CI = Confidence interval; mo = months; Non-Std = nonstandard; NR = not reached; NSCLC = non--small-cell lung cancer; Std = standard.Table 2Multivariable Adjustment for Confounding Factors for Overall Survival by Cox Proportional Hazards Regression Model Stratified by Immune-related Adverse EventsHR for Death (95% CI)*P*Standard vs. nonstandard group1.2 (0.3-4.8).824ECOG PS ≥ 2 vs. 0-12.4 (0.9-5.9).066Pembrolizumab alone vs. along with chemotherapy1.4 (0.6-3.3).446\< 50% vs. ≥ 50% PD-L1 TPS0.8 (0.3-1.9).591No. treatment cycles0.8 (0.6-0.9)**.001**[^4][^5]Table 3Multivariable Adjustment for Confounding Factors for Progression-free Survival by Cox Proportional Hazards Regression Model Stratified by Immune-related Adverse EventsHR for Disease Progression or Death (95% CI)*P*Standard vs. nonstandard group2.6 (0.7-9.6).157Never vs. current/former smoker4.2 (1.6-11.3)**.004**Pembrolizumab alone vs. along with chemotherapy2.7 (1.2-6.2)**.016**\< 50% vs. ≥ 50% PD-L1 TPS0.9 (0.4-2.1).873ECOG PS ≥ 2 vs. 0-10.8 (0.4-1.9).700No. of treatment cycles0.7 (0.6-0.8)**\<.001**[^6][^7]Figure 3Swimmer's Plot Showing Time on Pembrolizumab Treatment After First Nonstandard (Extended or Delayed) Pembrolizumab Cycle in the Nonstandard Group With Patients Distributed by the Indication SubgroupsAbbreviation: irAE = Immune-related adverse event.

Discussion {#sec4}
==========

We report here the real-world outcomes of patients with advanced NSCLC receiving pembrolizumab-based regimens with extended intervals or treatment delays owing to indications commonly encountered in routine clinical practice: irAEs, treatment-unrelated medical issues, and/or individual care preferences. Within the limitations discussed below, these patients had comparable outcomes with those who either received all (or up to 1 delayed cycle of) pembrolizumab at the FDA-approved label dosage of 200 mg every 3 weeks. We acknowledge that our results are hypothesis-generating only, but relevant in an arena where no other well-vetted data exists.

Most early pharmacokinetic and pharmacodynamic studies from phase I clinical trials of pembrolizumab evaluated doses between 2 and 10 mg/kg every 2 to 3 weeks.[@bib2] ^,^ [@bib15], [@bib16], [@bib17] These were the basis of a modeling/simulation study that evaluated the exposure-response relationship with extended pembrolizumab dosing interval of 6 weeks, albeit with a higher dose of 400 mg[@bib13]; this dosing schema was approved by the European Commission and recently by the FDA.[@bib18] ^,^ [@bib19] Whether extending pembrolizumab dosing intervals while keeping the dose at 200 mg will lead to the same predicted efficacy and safety has not been studied yet. Our data provides rationale for further evaluation of extended dosing intervals of pembrolizumab, particularly in patients with disease response or stabilization after the first 4 treatment cycles. This may be a more fiscally and logistically viable model, while improving flexibility and patient experience.

Recent pharmacoeconomic analyses comparing alternative dosing strategies of pembrolizumab (including weight-based dosing) to FDA-approved labels have estimated major cost savings for the health system with a personalized approach.[@bib20] ^,^ [@bib21] Randomized non-inferiority clinical trials designed with Bayesian methods would be the gold-standard for evaluating these extended dosing regimens in an effective and cost-efficient manner.[@bib9] ^,^ [@bib22], [@bib23], [@bib24] Alternatively, therapeutic drug monitoring for personalized dosing --- as commonly used for antibiotics and immunosuppressive agents --- to achieve plasma or serum drug concentrations within a known therapeutic range is another potential strategy that can be employed in prospective studies to minimize financial toxicity from drug and pharmacy costs in this growing population.[@bib9] ^,^ [@bib25] It would also be prudent to take into account the time-dependent reduction in clearance of immune checkpoint inhibitors in these studies.[@bib26] ^,^ [@bib27]

Limitations of this study include retrospective analysis, small sample size, confounding by indication, exclusion of patients who did not receive at least 4 pembrolizumab-based treatment cycles, and inclusion of patients treated only at tertiary academic cancer centers. These results are not applicable to patients whose disease progresses earlier in the treatment course and those being treated in other practice settings. Even though we employed a 6-month landmark survival analysis and multivariable regression to account for the guaranteed time bias and confounding variables, respectively, these biases persist. These findings require vetting in a large prospective manner. Moreover, it is not possible to draw any definitive conclusions when comparing the 3 predominant subgroups of the Non-Std group to the Std group owing to the small sample sizes. Tumor mutation burden was not included in the final adjusted model, as it was available for only approximately 50% of the patients and was not measured with a uniform assay.

Conclusions {#sec5}
===========

To the best of our knowledge, this is the first study to describe outcomes of patients with advanced NSCLC receiving pembrolizumab-based regimens at extended intervals owing to real-world situations commonly faced in routine clinical practice and unprecedented circumstances such as the COVID-19 pandemic. Within the limitations described above, our study provides rationale for prospectively evaluating the administration of the lowest and least frequent efficacious dose of pembrolizumab, particularly for patients with demonstrated disease stability or response for the first 3 to 6 months.

Clinical Practice Points {#sec5.1}
------------------------

•The most cost-effective administration frequency of pembrolizumab in advanced NSCLC has not been evaluated in clinical trials. Based on a modeling/simulation study, the dosing schedule of pembrolizumab at 400 mg every 6 weeks has been approved by the European Commission and the FDA.•In this multicenter retrospective cohort study, we found that a significant proportion of patients with advanced NSCLC receive pembrolizumab-based regimens with extended intervals or delays in routine clinical practice owing to irAEs, medical issues, and patient-physician preferences.•We found that these treatment delays or extended dosing intervals were not associated with worse outcomes after multivariable adjustment for confounding factors in the patients with advanced NSCLC who had received at least 4 cycles of pembrolizumab-based regimens.•To the best of our knowledge, this is the first study to describe outcomes of patients with advanced NSCLC receiving pembrolizumab-based regimens at extended intervals owing to real-world situations commonly faced in routine clinical practice.•Prospective evaluation of alternative dosing strategies in randomized non-inferiority clinical trials, with attention to time-dependent reduction in clearance of pembrolizumab and potential incorporation of personalized dosing with therapeutic drug monitoring is warranted.•Alternative dosing strategies may provide a more fiscally and logistically viable model, while improving flexibility and patient experience.
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Supplemental Data {#appsec1}
=================

Supplemental Table 1Patient Characteristics of the Screened PopulationIncluded Patients (N = 92)Excluded Patients (N = 58)Clinico-pathologic characteristics Median age, y (range)64.5 (37-87)69 (33-87) Female gender44 (48)31 (53) Smoking status, ever84 (91)52 (90) ECOG PS 0-175 (82)27 (47) ≥217 (18)28 (48) Not reported0 (0)3 (5) Histology Non-squamous70 (76)45 (78) Squamous15 (16)9 (15) Poorly differentiated7 (8)4 (7) Driver mutation *KRAS*33 (36)19 (33) *EGFR*6 (7)3 (5) Others3 (3)3 (5) None identified40 (43)25 (43) Not assessed10 (11)8 (14) PD-L1 TPS, % \<124 (26)8 (14) 1-4917 (18)15 (26) ≥5042 (46)31 (53) Not assessed9 (10)4 (7) TMB, mut/mB \<1020 (22)14 (24) ≥1030 (32)11 (19) Not assessed42 (46)33 (57)Treatment characteristics Line of pembrolizumab First line65 (71)39 (67) ≥Second line27 (29)19 (33) Treatment Monotherapy41 (45)35 (60) With chemotherapy51 (55)22 (38) Not known0 (0)1 (2) Treatment center BIDMC47 (51)34 (59) VMC45 (49)24 (41) Median no. treatment cycles (range)8 (4-41)2 (1-3) Any grade irAE, yes54 (59)16 (28) ≥Grade 3 irAE, yes28 (30)12 (21) Systemic immunosuppression for irAE, yes41 (45)16 (28)[^8][^9]Supplemental Table 2Reasons for Delays or Extensions in the Nonstandard GroupSerial No.SubgroupReason(s)1irAEArthritis, holidays2irAESynovitis, patient-physician preference3irAEHospitalization for adrenal insufficiency4irAEFatigue5irAEPneumonitis6irAEPneumonitis, adrenal insufficiency, fatigue7irAEToxic epidermal necrolysis8irAEThyroiditis9irAEPneumonitis, patient requested treatment break10Non-irAE medical issuesHospitalization for pneumonia, missed restaging scans, insurance issues, family issues11Non-irAE medical issuesMissed visits owing to depression, transportation issues12Non-irAE medical issuesHospitalization for postoperative wound infection13Non-irAE medical issuesPneumonia, travel plans, holidays, switched treatment to every 6 weeks after completing 2 years14Non-irAE medical issuesPneumonia, Gastrointestinal issues, travel plans15Non-irAE medical issuesOpen draining chest wall wound, holidays16Non-irAE medical issuesRespiratory symptoms (not pneumonitis), hospitalization for atrial fibrillation with rapid ventricular rhythm17PreferencePatient-physician preference18PreferencePatient-physician preference19PreferencePatient-physician preference20PreferencePatient-physician preference, insurance issues21PreferencePatient-physician preference, travel plans22PreferencePatient-physician preference, death in family, travel plans23PreferencePatient-physician preference, travel plans24PreferencePatient-physician preference, travel plans, scheduling issues owing to preference to see primary oncologist only25PreferencePatient-physician preference, holidays26PreferencePatient-physician preference, patient cancelled multiple appointments27PreferencePatient-physician preference[^10]Supplemental Table 3Univariate Analysis of Overall Survival by Cox Proportional Hazards Regression ModelHR for Death (95% CI)*P*Standard vs. nonstandard group6.9 (2.1-22.9)**.002**Age (years)1.0 (0.9-1.1).060Never vs. current/former smoker1.5 (0.6-4.0).85ECOG PS ≥ 2 vs. 0-11.8 (0.8-3.9).175\<50% vs. ≥50% PD-L1 TPS1.4 (0.7-2.9).90Later vs. first line of therapy0.5 (0.2-1.3).167Pembrolizumab alone vs. along with chemotherapy1.0 (0.5-2.1).944No. of treatment cycles0.8 (0.7-0.9)**\<.001**Absence vs. presence of any grade irAE2.2 (1.1-4.5)**.030**VMC vs. BIDMC0.8 (0.4-1.7).615[^11][^12]Supplemental Table 4Univariate Analysis of Progression-free Survival by Cox Proportional Hazards Regression ModelHR for Disease Progression or Death (95% CI)*P*Standard vs. nonstandard group8.5 (3.2-22.4)**\<.001**Age, y1.0 (0.9-1.0).411Never vs. current/former smoker1.9 (0.8-4.7).131ECOG PS ≥ 2 vs. 0-10.9 (0.6-1.6).964\<50% vs. ≥50% PD-L1 TPS1.2 (0.7-2.3).494Later vs. first line of therapy0.6 (0.3-1.3).190Pembrolizumab alone vs. along with chemotherapy0.8 (0.4-1.5).490No. treatment cycles0.7 (0.7-0.8)**\<.001**Absence vs. presence of any grade irAE1.5 (0.8-2.8).150VMC vs. BIDMC0.7 (0.4-1.3).242[^13][^14]Supplemental Figure 1Univariate Survival Curves in Patients With Advanced NSCLC Belonging to the Standard Group Versus Subgroups of the Nonstandard Group for Overall Survival (**A**) and Progression-free Survival (**B**)Abbreviations: CI = Confidence interval; irAE = immune-related adverse event; NR = not reached; NSCLC = non--small-cell lung cancer; Std = standard.
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[^1]: Current address for Glen J. Weiss: UNUM Therapeutics Inc, Cambridge, MA.

[^2]: Abbreviations: BIDMC = Beth Israel Deaconess Medical Center; CR = complete response; ECOG = Eastern Cooperative Oncology Group; irAE = immune-related adverse events; PR = partial response; PS = performance status; SD = stable disease; TMB = tumor mutational burden; TPS = tumor proportion score; VMC = Vidant Medical Center.

[^3]: Data are shown as n (%), unless specified.

[^4]: Abbreviations: CI = Confidence interval; ECOG = Eastern Cooperative Oncology Group; HR = hazard ratio; PD-L1 = programmed death-ligand 1; PS = performance status; TPS = tumor proportion score.

[^5]: Bold value is significant.

[^6]: Abbreviations: CI = Confidence interval; ECOG = Eastern Cooperative Oncology Group; HR = hazard ratio; PD-L1 = programmed death-ligand 1; PS = performance status; TPS = tumor proportion score.

[^7]: Bold values are significant.

[^8]: Abbreviations: BIDMC = Beth Israel Deaconess Medical Center; CR = complete response; ECOG = Eastern Cooperative Oncology Group; irAE = immune-related adverse events; PD-L1 = programmed death-ligand 1; PS = performance status; TMB = tumor mutational burden; TPS = tumor proportion score; VMC = Vidant Medical Center.

[^9]: Data shown as n (%), unless specified.

[^10]: Abbreviation: irAE = Immune-related adverse events.

[^11]: Abbreviations: BIDMC = Beth Israel Deaconess Medical Center; CI = confidence interval; ECOG = Eastern Cooperative Oncology Group; HR = hazard ratio; irAE = immune-related adverse events; PD-L1 = programmed death-ligand 1; PS = performance status; TPS = tumor proportion score; VMC = Vidant Medical Center.

[^12]: Bold values are significant.

[^13]: Abbreviations: BIDMC = Beth Israel Deaconess Medical Center; CI = confidence interval; ECOG = Eastern Cooperative Oncology Group; HR = hazard ratio; irAE = immune-related adverse events; PD-L1 = programmed death-ligand 1; PS = performance status; TPS = tumor proportion score; VMC = Vidant Medical Center.

[^14]: Bold values are significant.
